If semaglutide barely worked for you despite doing everything right, you're not imagining it — and it's not a willpower problem. A Stanford-led study published April 2026 identified a genetic variant carried by roughly 10% of people that makes GLP-1 drugs significantly less effective at the biological level.
"What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications." — Dr. Anna Gloyn, Stanford Medicine
The discovery: Published April 10, 2026 in Genome Medicine, a decade-long international study led by Stanford Medicine and ETH Zurich found that roughly 10% of people carry genetic variants in a gene called PAM that significantly reduce how well GLP-1 medications work — not because of willpower, diet, or dosing, but at the level of basic cell biology.
The strange paradox researchers found
Here's what makes this discovery genuinely surprising: researchers expected that people with the PAM variant would have lower levels of GLP-1 in their blood. Instead, they found the opposite. People with the variant had higher circulating GLP-1 — but the hormone was significantly less biologically effective. The signal was present. The body just wasn't responding to it properly.
The gene in question, PAM (peptidyl-glycine alpha-amidating monooxygenase), encodes the only enzyme in the human body capable of a chemical process called amidation — a modification required to make peptide hormones like GLP-1 fully potent and long-lasting. When PAM is impaired, GLP-1 gets made, gets released, but doesn't work as well once it gets where it's going.
The numbers — how big a difference does this actually make
~10%
Of the general population carries a PAM resistance variant
Stanford, April 2026
25%
Of non-carriers hit their target blood sugar goal after 6 months
vs variant carriers below
11.5%
Of p.S539W variant carriers hit the same target — less than half the rate
Same 6-month mark
In the meta-analysis of three clinical trials covering 1,119 participants, people carrying the p.S539W variant achieved their target HbA1c (blood sugar control) only 11.5% of the time after six months of GLP-1 treatment — compared to 25% for people without the variant. A second variant, p.D563G, showed a less severe but still significant effect, with 18.5% reaching target.
Why this specifically rules out "you're just not trying hard enough"
The most clinically important finding in the study: carriers of the PAM variant responded completely normally to other diabetes medications — metformin, sulfonylureas, and DPP-4 inhibitors all worked the same in carriers and non-carriers. The resistance is specific to the GLP-1 pathway. That specificity is what convinces researchers this is a real, targeted biological mechanism — not a confound from lifestyle, adherence, or other health factors.
What this means in plain terms: If you did everything correctly — proper injection technique, full titration schedule, adequate protein, resistance training — and semaglutide or another GLP-1 still produced disappointing results, genetics may be a real, measurable part of the explanation. This is not currently a commercially available test, but it validates an experience many patients have had with no clear explanation until now.
A second, related discovery from the same month
In April 2026, a separate large-scale study (23andMe, published in Nature, 27,885 participants) identified additional genetic variants affecting GLP-1 response — including one directly in the GLP-1 receptor gene itself (GLP1R) linked to weight loss outcomes, and a GIPR variant linked to increased nausea specifically on tirzepatide. Together, these two 2026 studies reveal that GLP-1 response varies by genetics at multiple biological layers: how the hormone is processed (PAM), and how strongly the receptor itself responds (GLP1R, GIPR).
What to actually do if you suspect this is you
- Rule out the common, fixable causes first. Most underperformance on GLP-1 has an identifiable, addressable cause — sub-therapeutic dosing, insufficient protein intake, or hormonal factors in perimenopausal women. See our full breakdown of the 7 most common reasons before assuming genetics is the explanation.
- Discuss switching mechanisms with your physician. Since the PAM resistance is specific to GLP-1 processing, medications that work through different or additional pathways — like tirzepatide's added GIP mechanism — may partially or fully bypass this specific resistance, though this hasn't been directly studied yet.
- Don't let this become a reason to give up. Researchers explicitly noted this could lead to better-tailored treatment, including potentially longer-acting GLP-1 formulations or insulin-sensitizing approaches that work alongside resistance rather than against it. This is an active, fast-moving research area.
✅ The bottom line
This research is genuinely validating for the estimated 1 in 10 people who tried a GLP-1 medication, did everything right, and still didn't get the results everyone else seems to be getting. It's not commercially testable yet, and it doesn't change today's treatment options — but it confirms that "this isn't working as well for me" has a real, measurable biological basis for some people, not just an explanation people invent to feel better.
Not getting the results you expected?
Our free Treatment Optimizer walks through the most common — and most fixable — reasons GLP-1 medications underperform, and gives you a personalized next-step recommendation.
Run the Treatment Optimizer →
Frequently asked questions
What is GLP-1 resistance?
GLP-1 resistance is a phenomenon identified by Stanford Medicine researchers in an April 2026 study, in which genetic variants in the PAM gene cause higher circulating GLP-1 hormone levels but significantly reduced biological effectiveness. It's estimated to affect roughly 10% of the general population, and was found to specifically reduce response to GLP-1 receptor agonist medications without affecting response to other diabetes medications like metformin.
Can I get tested for the PAM gene variant?
As of mid-2026, PAM variant testing is not yet a standard commercially available clinical test. The Stanford research was conducted as part of academic clinical trial analysis. Researchers have noted this discovery could eventually lead to predictive genetic testing to identify likely non-responders before starting treatment, but this is not currently part of routine clinical care.
If I have GLP-1 resistance, will tirzepatide work better than semaglutide?
This hasn't been directly studied yet for the PAM variant specifically. However, because tirzepatide activates both GLP-1 and GIP receptors (compared to semaglutide's single GLP-1 pathway), it's biologically plausible that the added GIP mechanism could partially offset GLP-1-specific resistance. This is a reasonable topic to discuss with your physician but is not yet confirmed by direct research.